Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in patients with nonmetastatic CRPC receiving darolutamide.
Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.
Greater visceral and thigh subcutaneous fat are associated with higher risks of advanced and fatal prostate cancer (PCa), according to a new prospective study. In addition, visceral fat is associated with a higher risk of these outcomes among men with a lower body mass index (BMI). Investigators found no association between any adiposity measure and…
Addition of enzalutamide vs another nonsteroidal anti-androgen to standard of care is associated with significant improvement in overall survival among men with metastatic hormone-sensitive prostate cancer.
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
